Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin

Biochemical Pharmacology

Volumn 51, Issue 7, 1996, Pages 931-940

  Fornari Jr , Frank A ^a   Jarvis, W David ^a   Grant, Steven ^a   Orr, Michael S ^a   Randolph, Joyce K ^a   White, Frances K H ^b   Gewirtz, David A ^a,b  

^a Depts Med and Pharmacol Toxicol   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; c myc; doxorubicin; MCF 7

Indexed keywords

DNA FRAGMENT; DOXORUBICIN; GYRASE INHIBITOR; MESSENGER RNA;

ARTICLE; BREAST TUMOR; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; GEL ELECTROPHORESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL; REGULATORY MECHANISM; SPECTROFLUOROMETRY;

EID: 0029936580     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00050-0     Document Type: Article

References (62)

1. Henderson IC and Canellos GP, Cancer of the breast: The past decade. N Engl J Med 302: 78-90, 1980.
2. Fornari FA, Randolph JK, Yalowich JC, Ritke MK and Gewirtz DA, Interference with DNA unwinding by doxorubicin in MCF-7 breast tumor cells. Mol Pharmacol 45: 649-656, 1994.
3. Robert J, Illiadis A, Hoerni B, Cano J, Durand M and Lagarde C, Pharmacokinetics of adriamycin in patients with breast cancer: Correlation between pharmacokinetic parameters and clinical short-term response. Eur J Cancer Clin Oncol 18: 739-745, 1982.
4. Brenner DE, Galloway S, Cooper J, Noone R and Hande KR, Improved high-performance liquid chromatography assay of doxorubicin: Detection of circulating aglycones in human plasma and comparison with thin-layer chromatography. Cancer Chemother Pharmacol 14: 139-145, 1985.
5. Fornari FA, Jarvis WD, Grant S, Orr MS, Randolph JK, White FKH, Mumaw VR, Lovings ET, Freeman RH and Gewirtz DA, Induction of differentiation and non-apoptotic cell death associated with nascent DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells exposed to a therapeutically relevant concentration of doxorubicin. Cell Growth Differ 5: 723-733, 1994.
6. Watson PH, Pon RT and Shiu RPC, Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res 51: 3996-4000, 1991.
7. Shiu RPC, Watson PH and Dubik D, c-myc oncogene expression in estrogen-dependent and -independent breast cancer, Clin Chem 39:353-355, 1993.
8. Kreipe H, Feist H, Fischer L, Felgner J, Heidorn K, Mettler L and Parwaresch R, Amplification of c-myc but not c-erbB-2 is associated with high proliferative capacity in breast cancer. Cancer Res 53: 1956-1961, 1993.
9. Escot C, Theillet C, Lidereau R, Spyratos F, Champeme M-H, Gest J and Callahan R, Genetic alteration of the c-myc protooncogene (MYC) in human primary breast cancinomas. Proc Natl Acad Sci USA 83: 4834-4838, 1986.
10. Martiani-Costantini R, Escot C, Theillet C, Gentile A, Merlo G, Lidereau R and Callahan R In situ c-myc expression and genomic status of the c-myc locus in infiltrating ductal carcinomas of the breast. Cancer Res 48: 199-205, 1988.
11. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ and Hancock DC, Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128, 1992.
12. Amati B, Littlewood TD, Evan GI and Land H, The c-myc protein induces cell cycle progression and apoptosis through dimerization with MAX. EMBO J 12: 5083-5087, 1993.
13. Gewirtz DA, Orr MS, Fornari Fa, Randolph JK, Yalowich JC, Ritke MK, Povirk LF and Bunch RT, Dissociation between bulk damage to DNA and the antiptoliferative activity of teniposide (VM-26) in the MCF-7 breast tumor cell line: Evidence for induction of gene-specific damage and alterations in gene expression. Cancer Res 53: 3547-3554, 1993.
14. Bunch RT, Povirk LF, Orr MS, Randolph JK, Fornari FA and Gewirtz DA, Influence of amsacrine (m-AMSA) on bulk and gene-specific DNA damage and c-myc expression in MCF-7 breast tumor cells. Biochem Pharmacol 47: 317-329, 1994.
15. Mosmann T, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
16. Munger C, Ellis A, Woods K, Randolph J, Yanovich S and Gewirtz DA, Evidence for inhibition of growth related to compromised DNA synthesis in the interaction of daunorubicin with H-35 rat hepatoma. Cancer Res 48: 2404-2411, 1988.
17. Fried J, Perez AG and Clarkson BD, Rapid hypotonic method for flow cytofluorometry of monolayer cell cultures. Some pitfalls in staining and data analysis. J Histochem Cytochem 26: 921-933, 1978.
18. 3, WI-38, and 2RA cells. J Biol Chem 255: 3585-3590, 1980.
19. Cesarone C, Bolognesi C and Santi L, Improved microfluorometric DNA detetmination in biological material using Hoechst 33258. Anal Biochem 100: 188-197, 1979.
20. Jarvis WD, Kolesnick RN, Fornari FA, Traylor RS, Gewirtz DA and Grant S, Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. Proc Natl Acad Sci USA 91: 73-77, 1994.
21. Ellis AL, Munger CE, Bunch RT, Woods KE, Randolph JK, Boise L, Swerdlow PS, Zwelling LA, Hinds M, Yanovich S and Gewirtz DA, Components of intrinsic drug resistance in the rat hepatoma. Biochem Pharmacol 43: 331-342, 1992.
22. Chrigwin JM, Pryzbyla HE, MacDonald RJ and Rutter WJ, Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18: 5294-5299, 1984.
23. Thomas PS, Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc Natl Acad Sci USA 77: 5201-5205, 1990.
24. Barlogie B, Drewinko B, Johnston DA and Freireich EJ, The effect of adriamycin on the cell cycle traverse of a human lymphoid cell line. Cancer Res 36: 1975-1979, 1976.
25. Rius C, Zorrilla AR, Cabanas C, Mata F, Bernabeu C and Aller P, Differentiation of human promonocytic leukemia U-937 cells with DNA topoisomerase II inhibitors: Induction of vimentin gene expression. Mol Pharmacol 39: 442-448, 1990.
26. O'Conner PM, Wasserman K, Sarang M, Magrath I, Bohr VA and Kohn KW, Relationship between DNA cross-links, cell cycle, and apoptosis in Burkitt's lymphoma cell lines differing in sensitivity to nitrogen mustard. Cancer Res 51: 6550-6557, 1991.
27. Skladanowski A and Konopa J, Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumor cells. Biochem Pharmacol 46: 375-382, 1993.
28. Lang Y-H, Priebe W and Perez-Soler R, Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells. Cancer Res 53: 1845-1852, 1993.
29. Gerschenson LE and Rotello RJ, Apoptosis: A different type of cell death. FASEB J 6: 2450-2455, 1992.
30. Solary E, Bertrand R and Pommier Y, Apoptosis of human leukemic HL-60 cells induced to differentiate by phorbol ester treatment. Leukemia 8: 792-797, 1994.
31. Armstrong DK, Isaacs JT, Ottaviano YL and Davidson NE, Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468. Cancer Res 52: 3418-3424, 1992.
32. Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman J, Wakeling AE, Walker PR and Sikorska M, Apoptotic death in epithelial cells: Cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 12: 3679-3684, 1993.
33. Jarvis DW, Fornari FA, Browning JF, Gewirtz DA, Kolesnick RN and Grant S, Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemic cells. J Biol Chem 269: 31685-31692, 1994.
34. Orr MS, Fornari FA, Randolph JK and Gewirtz DA. Transcriptional down-regulation of c-myc expression in the MCF-7 breast tumor cell line by the topoisomerase II inhibitor, VM-26. Biochim Biophys Acta 1262: 139-145, 1995.
35. Dean M, Levine RA, Ran W, Kindy MS, Sonenshein GE and Campisi J, Regulation of c-myc transcription and mRNA abundance by serum growth factors and cell contact. J Biol Chem 261: 9161-9166, 1986.
36. Vichy P and Tritton TR, Stimulation of growth in human and murine cells by adriamycin. Cancer Res 49: 2679-2682, 1989.
37. Kelly K, Cochran BH, Stiles CD and Leder P, Cell specific regulation of the c-myc gene by lymphocyte mitogens and platelet derived growth factors. Cell 35: 603-610, 1983.
38. Fritsche M, Haessler C and Brandner G, Induction of nuclear accumulation of the tumor suppressor protein p53 by DNA-damaging agents. Oncogens 8: 307-318, 1993.
39. Nelson WG and Kastan MB, DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14: 1815-1823, 1994.
40. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB, Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7495, 1992.
41. Stewart N, Hicks GG, Paraskevas F and Mowat M, Evidence for a second cell cycle block at G2/M by p53. Oncogens 10: 109-115, 1995.
42. Guillouf C, Rosselli F, Krishnaraju K, Moustacchi E, Hoffman B and Liebermann DA, p53 involvement in control of G2 exit of the cell cycle: Role in DNA damage-induced apoptosis. Oncogene 10: 2263-2270, 1995.
43. Shibuya H, Yoneyama M, Ninomiya-Tsuji J, Matsumoto K and Taniguchi T, IL-2 and EGF receptors stimulate the hematopoietic cell cycle via different signaling pathways: Demonstration of a novel role for c-myc. Cell 70: 57-67, 1992.
44. Seth A, Gupta S and Davis RJ, Cell cycle regulation of the c-myc transcriptional activation domain. Mol Cell Biol 13: 4125-4136, 1993.
45. Levy N, Yonish-Rouach E, Oren M and Kimchi A, Complementation by wild-type p53 of interleukin-6 effects on Ml cells: Induction of cell cycle exit and cooperativity with c-myc suppression. Mol Cell Biol 13: 7942-7952, 1993.
46. Studzinski GP, Brevli ZS, Feldman SC and Watt R, Participation of c-myc protein in DNA synthesis of human cells. Science 234: 467-470, 1986.
47. Ariga H, Imamura Y and Iguchi-Ariga SMM, DNA replication origin and transcriptional enhancer in c-myc gene share the c-myc protein binding sequences. EMBOJ 8: 4273-4279, 1989.
48. van der Burg B, van Selm-Miltenburg AJP, de Laan SW and van Zoelen EJJ, Direct effects of estrogen on c-fos and c-myc protooncogene expression and cellular proliferation in human breast cancer cells. Mol Cell Endocrinol 64: 223-228, 1989.
49. Wosikowski K, Eppenberger U, Küng W, Nagamine Y and Mueller H, c-fos, c-jun and c-myc expressions are not growth rate limiting for the human MCF-7 breast cancer cells. Biochem Biophys Res Commun 188: 1067-1076, 1992.
50. Zakeri Z, Bursch W, Tennisword M and Lockshin RA, Cell death: Programmed, apoptosis, necrosis or other? Cell Death Differ 2: 87-96, 1995.
51. Kryprianou N, English HF, Davidson NE and Isaacs JT, Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51: 162-166, 1991.
52. Wärri AM, Huovinen RL, Laine AM, Martikainen PM and Härkönen PL, Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 85: 1412-1418, 1993.
53. Wang TTW and Phang JM, Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 55: 2487-2489, 1995.
54. Teixeira C, Reed JC and Pratt MAC, Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55: 3902-3907, 1995.
55. Shao Z-M, Dawson Ml, Li XS, Rish AK, Sheikh MS, Han Q-H, Ordonez JV, Shroot B and Fontana JA, p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 11: 493-504, 1995.
56. Hermeking H and Eick D, Mediation of c-Myc induced apoptosis by p53. Science 265: 2091-2093, 1994.
57. wafl/cip1. Genes Dev 8: 2817-2830, 1994.
58. Kiguchi K, Glesne D, Chub CH, Fijiki H and Huberman E, Differential induction of apoptosis in human breast tumor cells by okadaic acid and related inhibitors of protein phosphatases 1 and 2A. Cell Growth Differ 5: 995-1004, 1994.
59. s sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 55: 2507-2510, 1995.
60. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR and Cotter TG, BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83: 1179-1187, 1994.
61. Jarvis WD, Povirk LF, Turner AJ, Traylor RS, Gewirtz DA, Pettit GR and Grant S, Effects of bryostatin 1 and other pharmacological activators of protein kinase C on l1-[β-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol 47: 839-852, 1994.
62. Boudreau N, Sympson CJ, Werb Z and Bissell MJ, Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267: 891-893, 1995.